Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer

Area of Science:

• Oncology
• Systems Biology
• Molecular Biology

Background:

• Late-stage prostate cancer (PCa) lacks effective treatments, necessitating novel therapeutic targets.
• Understanding signaling pathway crosstalk is crucial for advancing PCa therapy.

Purpose of the Study:

• To identify novel co-targets for advanced PCa treatment using a network-based systems biology approach.
• To elucidate the regulatory mechanisms of signaling pathways in PCa progression.

Main Methods:

• Development of XDeath, a network-based systems biology approach integrating gene regulatory and protein-protein interaction networks.
• Analysis of signaling pathway crosstalk in PCa progression.
• Investigation of the mechanistic interplay between polo-like kinase 1 (Plk1) and DNA methyltransferase 3A (DNMT3a).

Main Results:

• Plk1 and DNMT3a signaling pathways are significantly enhanced during PCa progression.
• These pathways cooperatively regulate autophagy, a common cell death mode in PCa.
• A negative feedback loop exists between Plk1 and DNMT3a, involving phosphorylation, degradation, and transcriptional repression.
• Combined inhibition of DNMT3a (using 5-Aza) and Plk1 demonstrates synergistic suppression of PCa.

Conclusions:

• Plk1 and DNMT3a represent critical regulators of PCa progression and autophagy.
• Targeting the Plk1-DNMT3a axis offers a novel therapeutic strategy for advanced PCa.
• Combination therapy with DNMT inhibitors and Plk1 inhibitors shows significant potential for synergistic PCa treatment.